Blood Pressure Medication Class Action Settlement: Valsartan, Losartan, Irbesartan
Last updated May 27, 2026 · By Class Action Buddy
⚠️ FILING WINDOW CLOSED
The deadline to file a claim against Aurobindo, Hetero, and Vivimed for contaminated valsartan, losartan, and irbesartan was June 2, 2026. The settlement is no longer accepting new claims, and the final approval hearing was held on June 30, 2026.
See other open pharmaceutical and health settlements below — and download Class Action Buddy so you don't miss the next one.
A $15.2 million class action settlement was reached with three pharmaceutical manufacturers — Aurobindo Pharma, Hetero Drugs, and Vivimed Labs — over claims they sold valsartan, losartan, and irbesartan blood pressure medications contaminated with probable carcinogens (NDMA and NDEA) between 2012 and 2019.
The filing window for class members closed on June 2, 2026, and the court held its final approval hearing on June 30, 2026. If you didn't file in time, you can no longer recover compensation from this specific settlement, though similar pharmaceutical contamination cases continue to be filed and may become available in the future.
This page remains as a reference for those researching the contamination crisis, the manufacturers involved, and the structure of pharmaceutical class action settlements. For currently open opportunities, see the open no-proof settlements and pharmaceutical and health settlements pages.
Background — Why Aurobindo, Hetero, and Vivimed Are Paying
The lawsuit stems from widespread contamination of popular blood pressure medications with dangerous chemical impurities. Between 2012 and 2019, Aurobindo Pharma, Hetero Drugs, and Vivimed Labs allegedly manufactured and distributed valsartan, losartan, and irbesartan tablets containing NDMA (N-nitrosodimethylamine) and NDEA (N-nitrosodiethylamine). Both substances are classified as probable human carcinogens.
The contamination crisis began unfolding publicly in 2018 when the FDA started issuing recalls for affected medications. Testing revealed that certain batches contained levels of these carcinogenic impurities far exceeding acceptable limits. The contamination was traced to manufacturing processes and facilities used by these pharmaceutical companies.
Multiple lawsuits were filed against the manufacturers, alleging they knew or should have known about the contamination but failed to properly test their products or warn patients and healthcare providers. Plaintiffs claimed the companies prioritized profits over patient safety, exposing millions of Americans to unnecessary cancer risks while seeking treatment for hypertension and heart conditions.
Who Is Eligible
You may be eligible for this settlement if you're a United States resident who purchased valsartan, losartan, or irbesartan medications manufactured by Aurobindo Pharma, Hetero Drugs, or Vivimed Labs during the class period (primarily 2012-2019). This includes both prescription purchases and any over-the-counter versions of these blood pressure medications.
The settlement covers anyone who bought these specific medications regardless of how they were purchased - whether through insurance, Medicare, Medicaid, or cash payments. You're eligible whether you bought the medications for yourself or on behalf of a family member, and whether you experienced health problems or not.
Importantly, you don't need to keep prescription records, receipts, or pharmacy documentation to participate. The settlement administrators understand that most people don't retain medication packaging or purchase records from several years ago. You simply need to reasonably recall purchasing these medications from the defendant manufacturers during the relevant time period to submit a valid claim.
How Much You Can Receive
The $15.2 million settlement fund will be divided among all valid claimants who submit approved claims. Individual payout amounts will depend on the total number of people who participate in the settlement, as well as the specific details of each person's claim.
Claimants may be entitled to different payment levels based on factors such as how long they took the contaminated medications and whether they can document their purchases. However, the settlement specifically accommodates people without proof of purchase, ensuring that lack of documentation won't disqualify eligible claimants.
After deducting attorney fees, administrative costs, and other settlement expenses, the remaining funds will be distributed to class members. While exact per-person amounts won't be known until the claims process closes, similar pharmaceutical settlements have typically resulted in payments ranging from modest amounts to several hundred dollars per claimant.
Filing Process (Historical Reference)
While the claim window was open, claims were filed through the official administrator's portal at sartanmedicationsettlement.com. Class members submitted basic personal information along with which specific drugs (valsartan, losartan, or irbesartan) they took and approximately when. Prescription records and receipts were not required.
The filing deadline of June 2, 2026 has now passed, and the final approval hearing was held on June 30, 2026. New claim submissions are no longer being accepted.
If you missed this deadline, the missed deadline guide explains your remaining options. Going forward, Class Action Buddy can notify you when similar pharmaceutical settlements open — so you never have to remember a date.
Frequently Asked Questions
Can I still file a claim?
No. The filing deadline for this settlement was June 2, 2026, and the window is now closed. The final approval hearing was held on June 30, 2026.
Are there similar pharmaceutical settlements still open?
Yes. New pharmaceutical contamination, drug-pricing, and adverse-event class actions are filed regularly. Browse our health and supplement settlements page for current opportunities, or download Class Action Buddy to get notified automatically.
Why was this settlement filed?
The lawsuit alleged Aurobindo Pharma, Hetero Drugs, and Vivimed Labs sold valsartan, losartan, and irbesartan blood pressure medications contaminated with NDMA and NDEA, two chemicals classified as probable human carcinogens. The contamination crisis began publicly in 2018 when the FDA started issuing recalls.
What do I do if I missed the deadline?
For this specific settlement, the deadline cannot be extended. See our missed deadline guide for general options, and set up Class Action Buddy notifications so you never miss the next one.
The Aurobindo, Hetero, and Vivimed valsartan/losartan/irbesartan settlement closed on June 2, 2026. While the filing window has passed, the case stands as a significant example of how class action mechanisms compensate consumers for pharmaceutical contamination — even years after the products were recalled.
The best way to make sure you don't miss the next pharmaceutical or consumer-product settlement is to set up automatic notifications. Class Action Buddy tracks open settlements daily and tells you which ones you're eligible for based on a one-time profile you set up.
Related guides
Hand-picked from our settlement library to give you the full picture.